In a report released yesterday, Jason Gerberry from Bank of America Securities maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $83.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason Gerberry has given his Buy rating due to a combination of factors that highlight the promising outlook for Ionis Pharmaceuticals. The company’s recent Innovation Day showcased significant advancements in their pipeline, particularly in wholly-owned programs. Notably, the initial clinical data on their follow-on APO-C3 siRNA demonstrated potential for less frequent dosing, which could enhance patient compliance and market competitiveness.
Additionally, Ionis provided a financial outlook that offered clarity on their path to cash flow breakeven by 2028, addressing a key concern for investors. The company’s strategic focus on olezarsen for severe hypertriglyceridemia (sHTG) and the promising Phase 3 data for zilganersen in Alexander disease further support the potential for future growth. These developments, along with the anticipation of catalysts in 2026, underpin Gerberry’s confidence in the stock’s upside potential.
According to TipRanks, Gerberry is a 5-star analyst with an average return of 8.8% and a 55.76% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, and Alkermes.
In another report released today, J.P. Morgan also upgraded the stock to a Buy with a $80.00 price target.